Defining the Extracellular Matrix of Rhabdomyosarcoma.

COL18A1 PLOD1/2 matrix rhabdomyosarcoma survival

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2021
Historique:
received: 02 09 2020
accepted: 05 01 2021
entrez: 12 3 2021
pubmed: 13 3 2021
medline: 13 3 2021
Statut: epublish

Résumé

Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma of childhood with a propensity to metastasize. Current treatment for patients with RMS includes conventional systemic chemotherapy, radiation therapy, and surgical resection; nevertheless, little to no improvement in long term survival has been achieved in decades-underlining the need for target discovery and new therapeutic approaches to targeting tumor cells or the tumor microenvironment. To evaluate cross-species sarcoma extracellular matrix production, we have used murine models which feature knowledge of the myogenic cell-of-origin. With focus on the RMS/undifferentiated pleomorphic sarcoma (UPS) continuum, we have constructed tissue microarrays of 48 murine and four human sarcomas to analyze expression of seven different collagens, fibrillins, and collagen-modifying proteins, with cross-correlation to RNA deep sequencing. We have uncovered that RMS produces increased expression of type XVIII collagen alpha 1 (COL18A1), which is clinically associated with decreased long-term survival. We have also identified significantly increased RNA expression of COL4A1, FBN2, PLOD1, and PLOD2 in human RMS relative to normal skeletal muscle. These results complement recent studies investigating whether soft tissue sarcomas utilize collagens, fibrillins, and collagen-modifying enzymes to alter the structural integrity of surrounding host extracellular matrix/collagen quaternary structure resulting in improved ability to improve the ability to invade regionally and metastasize, for which therapeutic targeting is possible.

Identifiants

pubmed: 33708626
doi: 10.3389/fonc.2021.601957
pmc: PMC7942227
doi:

Types de publication

Journal Article

Langues

eng

Pagination

601957

Informations de copyright

Copyright © 2021 Lian, Bond, Bharathy, Boudko, Pokidysheva, Shern, Lathara, Sasaki, Settelmeyer, Cleary, Bajwa, Srinivasa, Hartley, Bächinger, Mansoor, Gultekin, Berlow and Keller.

Déclaration de conflit d'intérêts

Authors ML and GS are employed by the company Omics Data Automation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Mol Genet Metab. 2000 Sep-Oct;71(1-2):212-24
pubmed: 11001813
EMBO J. 1998 Aug 3;17(15):4249-56
pubmed: 9687493
Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20002-7
pubmed: 22135462
Skelet Muscle. 2019 May 4;9(1):11
pubmed: 31054580
Mayo Clin Proc. 2012 May;87(5):475-87
pubmed: 22560526
Skelet Muscle. 2013 Nov 25;3(1):27
pubmed: 24274149
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Oncogene. 2014 Apr 10;33(15):1877-89
pubmed: 23665679
FEBS Lett. 1997 Sep 15;414(3):557-61
pubmed: 9323035
Dis Model Mech. 2017 Sep 1;10(9):1109-1115
pubmed: 28883017
Pediatr Blood Cancer. 2006 Mar;46(3):329-38
pubmed: 16261596
Biopolymers. 2012 Aug;97(8):607-16
pubmed: 22605552
Mol Cancer Ther. 2011 Apr;10(4):697-707
pubmed: 21447712
Biochim Biophys Acta. 2015 Dec;1850(12):2422-38
pubmed: 26367079
Stem Cells. 2013 Nov;31(11):2304-12
pubmed: 23897781
Cancer. 2004 Apr 15;100(8):1665-72
pubmed: 15073855
Cancer Res. 2009 Apr 1;69(7):2902-11
pubmed: 19339268
Clin Cancer Res. 2011 May 1;17(9):2757-66
pubmed: 21536546
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):161-6
pubmed: 24368846
Histopathology. 2009 Jun;54(7):873-9
pubmed: 19469909
PLoS One. 2017 Aug 17;12(8):e0183161
pubmed: 28817624
Oncogene. 2008 Nov 20;27(51):6550-60
pubmed: 18679424
Science. 2020 Sep 11;369(6509):1318-1330
pubmed: 32913098
J Biol Chem. 1982 Aug 25;257(16):9796-803
pubmed: 7050102
Cancer Cell. 2014 Aug 11;26(2):154-5
pubmed: 25117705
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Cancer Cell. 2011 Feb 15;19(2):177-91
pubmed: 21316601
Nat Genet. 2013 Aug;45(8):923-6
pubmed: 23770606
Biochim Biophys Acta. 2013 Nov;1833(11):2479-91
pubmed: 23602968
Genes Dev. 2014 Jul 15;28(14):1578-91
pubmed: 25030697
Genes Dev. 2004 Nov 1;18(21):2614-26
pubmed: 15489287
Cancer Discov. 2013 Oct;3(10):1190-205
pubmed: 23906982

Auteurs

Xiaolei Lian (X)

Pediatric Cancer Biology, Children's Cancer Therapy Development Institute, Beaverton, OR, United States.

J Steffan Bond (JS)

Department of Pathology, Oregon Health & Science University, Portland, OR, United States.

Narendra Bharathy (N)

Pediatric Cancer Biology, Children's Cancer Therapy Development Institute, Beaverton, OR, United States.

Sergei P Boudko (SP)

Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN, United States.

Elena Pokidysheva (E)

Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN, United States.

Jack F Shern (JF)

Pediatric Oncology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, United States.

Melvin Lathara (M)

Bioinformatics, Omics Data Automation, Beaverton, OR, United States.

Takako Sasaki (T)

Department of Matrix Medicine, Oita University, Oita, Japan.

Teagan Settelmeyer (T)

Pediatric Cancer Biology, Children's Cancer Therapy Development Institute, Beaverton, OR, United States.

Megan M Cleary (MM)

Pediatric Cancer Biology, Children's Cancer Therapy Development Institute, Beaverton, OR, United States.

Ayeza Bajwa (A)

Pediatric Cancer Biology, Children's Cancer Therapy Development Institute, Beaverton, OR, United States.

Ganapati Srinivasa (G)

Bioinformatics, Omics Data Automation, Beaverton, OR, United States.

Christopher P Hartley (CP)

Department of Anatomic & Clinical Pathology, Mayo Clinic, Rochester, MN, United States.

Hans Peter Bächinger (HP)

Department of Biochemistry and Molecular Biology, Shriners Hospital for Children, Portland, OR, United States.

Atiya Mansoor (A)

Department of Pathology, Oregon Health & Science University, Portland, OR, United States.

Sakir H Gultekin (SH)

Department of Pathology, Oregon Health & Science University, Portland, OR, United States.

Noah E Berlow (NE)

Pediatric Cancer Biology, Children's Cancer Therapy Development Institute, Beaverton, OR, United States.

Charles Keller (C)

Pediatric Cancer Biology, Children's Cancer Therapy Development Institute, Beaverton, OR, United States.

Classifications MeSH